Lashelle Barmore
Family Medicine · Birmingham, ALNPI 1902177611
Payments from drug & device makers
Across 1,283 payments — averaging $378.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$242K
- Corcept Therapeutics$137K
- Dexcom, Inc.$30K
- Medtronic$29K
- Lilly USA, LLC$29K
- AstraZeneca$10K
- plus $7K from 32 others
What the payments were for
- Consulting fees$39,8058%
- Speaking & faculty fees$365,92475%
- Travel & lodging$57,50412%
- Food & beverage$22,2535%
- Education$1240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$134,923
- RYBELSUS$106,533
- Ozempic$102,077
- DEXCOM G7 GSS (161)$29,564
- TRULICITY$22,596
- Tresiba$9,698
- FARXIGA$9,124
- INPEN SMART INSULIN DELIVERY SYSTEM$7,266
- DEXCOM STELO GLUCOSE BIOSENSOR$7,256
- Minimed 670G System$4,840
- Victoza$4,590
- InPen$3,575
- DISEASE STATE$2,218
- Xultophy 100/3.6$1,755
- Minimed 770G System$1,445
- MINIMED 780G$256
- Kerendia$226
- BREZTRI$151
- XARELTO$146
- Minimed 630G$143
How this compares
$485,610 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 306 | $497,649 |
| FarxigaDapagliflozin Propanediol | 202 | $220,969 |
| RybelsusSemaglutide | 69 | $136,675 |
| JardianceEmpagliflozin | 114 | $125,788 |
| MounjaroTirzepatide | 69 | $102,621 |
| KerendiaFinerenone | 29 | $34,410 |
| TrulicityDulaglutide | 19 | $31,777 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $30,770 |
| LinzessLinaclotide | 18 | $27,662 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $25,433 |
| EliquisApixaban | 21 | $18,933 |
| JanuviaSitagliptin Phosphate | 12 | $13,570 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $12,229 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $11,754 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 29 | $6,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $241,840 | $634,324375 claims |
| AstraZenecaFarxiga | $10,447 | $220,969202 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $29,007 | $140,426101 claims |
| Boehringer IngelheimJardiance | $229 | $125,788114 claims |
| GSKTrelegy Ellipta, Shingrix | $19 | $37,21258 claims |
| BayerKerendia | $331 | $34,41029 claims |
| AbbVieLinzess | $740 | $27,66218 claims |
| PfizerEliquis | $330 | $18,93321 claims |
| MerckJanuvia | $76 | $13,57012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Birmingham
- Michael VaughnBirmingham$9.9M
- Song YuBirmingham$1.7M
- Nova LawBirmingham$649K
- Scott WeisbergBirmingham$38K
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.